Therapy of HCV in patients on programmed hemodialysis; analysis of multicenter observational program for patients treated with peginterferon alfa-2a

Chronic hepatitis C (CHC) remains a serious problem for patients with the end-stage kidney disease on renal replacement therapy. However there is no uniform concept of approaches to antiviral HCV therapy in these patients. Objective of the study: to investigate the efficacy and safety of peginterferon alfa-2a (Peg-IFN-a2а) monotherapy in HCV patients on hemodialysis (HD). Materials and methods: the study included 26 patients with HCV (M: 10 and F: 16) aged 22 to 58 years treated at 5 dialysis centers in various regions of Russia. The viral load was 4,8 ± 1,5 log₁₀ IU/ml. Genotype 1 was identified in 12 (48%) patients, non-1 genotype was identified in 13 (52%) patients. ALT activity was 29,6 ± 18,5 IU/L. Liver needle biopsy was performed in 10 patients. Knodell HAI score was 5,5 ± 1,4. Fibrosis stage 1 (by METAVIR score) was determined in 6 patients, fibrosis stage 2 was revealed in 4 patients. All patients were assigned to receive peginterferon-a2а at a dose of 135 µg/week for 48 weeks. Results of the study: early virological response (EVR) was reported in 22 out of 26 (84,6%) patients. Sustained virological response (SVR) was achieved in 15 out of 26 patients (57,7%). The correlation between EVR and SVR was confirmed: SVR was reported in 13 out of 21 patients with EVR (61,9%) whereas among 4 patients without EVR, only 1 patient (25%) had SVR (р = 0,039). Conclusions: the efficacy and safety of peginterferon-a2а monotherapy in CHC was confirmed in patients on HD.

программный гемодиализ, хронический гепатит С, пэг-интерферона-a2а, programmed dialysis, chronic C hepatitis, peginterferon-a2а

1. Akhan S.C., Kalender B., Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection // Infection. 2008. Vol. 36 (4). P. 341–344.

2. Ayaz C., Celen M.K., Yuce U.N., and Geyik M.F. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C // World Journal of Gastroenterology. Vol. 14 (2). P. 255–259.

3. Casanovas-Taltavull T., Baliellas C., Benasco C. et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation // Am. J. Gastroenterol. 2001. Vol. 96 (4). P. 1170–1177.

4. Casanovas-Taltavull T., Baliellas C., Llobet M. et al. Preliminary results of treatmentwith pegylated interferon alpha2a for chronic hepatitis C virus in kidney transplant candidates on hemodialysis // Transplantation Proceedings. 2007. Vol. 39 (7). P. 2125–2127.

5. Covic A., Maftei I.D., Mardare N.G.I. et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit // Journal of Nephrology. Vol. 19 (6), P. 794–801.

6. Craxi A. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. European Association for the Study of the Liver // J. Hepatol. 2011. Vol. 55 (2). P. 245–264.

7. Espinosa M., Arenas M.D., Aumente M.D. et al. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients // Clinical Nephrology. 2007. Vol. 6. P. 366–373.

8. Fabrizi F., Dulai G., Dixit V. et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients // Aliment. Pharmacol. Ther. 2003. Vol. 18 (11–12). P. 1071–1081.

9. Finni P.E., Souza E.R., Rioja S. et al. Is hepatitis C a risk factor to posttransplant diabetes mellitus after renal transplantation in patients using tacrolimus? // Transplant. Proc. 2004. Vol. 36 (4). P. 884–885.

10. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. 2002. Vol. 347. P. 975–982.

11. Gentil M.A., Luna E., Rodriguez-Algarra G. et al. Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C // Nephrol. Dial. Transplant. 2002. Vol. 17 (5). P. 887–891.

12. Ghany M.G., Strader D.B., Thomas D.L. et al. Diagnosis, management, and treatment of hepatitis C: an update // Hepatology. 2009. Vol. 49. P. 1335–1374.

13. Gordon C.E., Uhlig K., Schmid C.H. et. al. Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis // Clin. J. Am. Soc. Nephrol. 2011. Vol. 6 (9). P. 2226–2234.

14. Guh J.Y., Lai Y.H., Yang C.Y. et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients // Nephron. 1995. Vol. 69. P. 459–465.

15. Hadziyannis S.J., Sette H., Morgan T.R. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose // Ann. Intern. Med. 2004. Vol. (140). P. 346–355.

16. Kalantar-Zadeh K., McAllister C.J., Miller L.G. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study // Nephrol Dial Transplant. 2005. Vol. 20 (8). P. 1662–1669.

17. Kamar N., Toupance O., Buchler M. et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation // J. Am. Soc. Nephrol. 2003. Vol. 14 (8). P. 2092–2098.

18. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease // Kidney Int. 2008. Suppl. (109). P. 1–99.

19. Knodell R.G., Ishak K.G., Black W.C. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis // Hepatology. 1981. Vol. 4. P. 431.

20. Liu C.H., Liang C.C., Lin J.W. et al. Pegylated interferon alfa-2a versus standard interferon alfa-2a for treatment naive dialysis patients with chronic hepatitis C: a randomized study // Gut. 2008. Vol. 57 (4). P. 525–530.

21. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial // Lancet. 2001. Vol. 358. P. 958–965.

22. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications // Gut. 2006. Vol. 55 (9). P. 1350–1359.

23. Marcellin P., Hadziyannis S.J., Berg T. et al. Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin // Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver in Barcelona, Spain. April 11–15. 2007. EASL Abstract #613.

24. McHutchison J.G., Manns M., Patel K. et al. Adherence to combination therapy enhances sustained response in genotype 1infected patients with chronic hepatitis C // Gastroenterology. 2002. 1231061–1069.1069.

25. Mukherjee S., Gilroy R.K., McCashland T.M., Schafer D.F. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study // Transplantation Proceedings. 2003. Vol. 35 (4). P. 1478–1479.

26. Peck-Radosavljevic M., Boletis J., Besisik F. et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease // Clin. Gastroenterol. Hepatol. 2011. Vol. 9 (3). P. 242–248.

27. Rao V.K., Ma J. Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients // Transplantation. 1996. Vol. 62. P. 1765–1769.

28. Rendina M., Schena A., Castellaneta N.M. et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant // J. Hepatol. 2007. Vol. 46 (5). P. 768–774.

29. Rostaing L., Chatelut E., Payen J.L. et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications // J. Am. Soc. Nephrol. 1998. Vol. 9 (12). P. 2344–2348.

30. Russo M.W., Ghalib R., Sigal S. et al. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C // Nephrology Dialysis Transplantation. 2006. Vol. 21 (2). P. 437–443.

31. Sikole A., Dzekova P., Selja N. et al. Treatment of hepatitis C in haemodialysis patients with pegylated interferon alpha2a as monotherapy // Renal Failure. 2008. Vol. 29. P. 961–966.

32. Sporea I., Popescu A., Sirli R. et al. Pegylated interferon alpha2a treatment for chronic hepatitis C in patients on chronic hemodialysis // World Journal of Gastroenterology. 2006. Vol. 12. P. 4191–4194.

33. Thévenot T., Regimbeau C., Ratziu V. et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update // J. Viral Hepat. 2001. Vol. 8 (1). P. 48–62.

34. Ucmak H., Kokoglu O.F., Hosoglu S. et al. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients // Renal Failure. 2008. Vol. 30 (2). P. 227–232.

35. Werner T., Aqel B., Balan V. et al. Treatment of hepatitis C in renal transplantation candidates: a single-center experience // Transplantation. 2010. Vol. 90. P. 407–411.